US company TerraPower Isotopes announced it is producing actinium-225 (Ac-225) at commercial scale by harvesting the isotope from thorium-229 decay, which is derived from legacy US nuclear material.
The company, a subsidiary of the Bill Gates-founded nuclear reactor company TerraPower, said it us now providing sustained access to highly pure Ac-225 to the global pharmaceutical community through weekly production runs.
As a result, TerraPower Isotopes’ Ac-255, after further manufacturing, is now used in multiple drug developer’s radiopharmaceuticals in human clinical trials across the globe.
“This scale up of production capacity of TerraPower Isotopes’ actinium-225 opens a new chapter in the development of cancer treatment options, and I’m proud to be part of the journey,” said Scott Claunch, president of TerraPower Isotopes.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
